These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33283892)

  • 1. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia.
    Zhou Y; Xu P; Li H; Wang F; Yan H; Liang W; Xiang D; Zhang B; Banh HL
    Br J Clin Pharmacol; 2021 Jul; 87(7):2838-2846. PubMed ID: 33283892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic analysis of high-dose tigecycline, by Monte Carlo simulation, in plasma and sputum of patients with hospital-acquired pneumonia.
    Qin X; Kong L; Wu C; Zhang X; Xie M; Wu X
    J Clin Pharm Ther; 2022 Dec; 47(12):2312-2319. PubMed ID: 36479719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.
    Bhavnani SM; Rubino CM; Hammel JP; Forrest A; Dartois N; Cooper CA; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1065-72. PubMed ID: 22143524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
    Rubino CM; Forrest A; Bhavnani SM; Dukart G; Cooper A; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5180-6. PubMed ID: 20921315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis based on Monte Carlo simulation: How effective is tigecycline in routine antimicrobial therapy?
    Jin L; Liu X; Ren F; Liu Y; Sun N; Bai H; Jiang K; Wu S; Fan G
    Int J Clin Pharmacol Ther; 2021 Jul; 59(7):496-505. PubMed ID: 33960299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline.
    Leng B; Yan G; Wang C; Shen C; Zhang W; Wang W
    J Glob Antimicrob Resist; 2021 Jun; 25():315-322. PubMed ID: 33957288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
    Lodise TP; Van Wart S; Sund ZM; Bressler AM; Khan A; Makley AT; Hamad Y; Salata RA; Silveira FP; Sims MD; Kabchi BA; Saad MA; Brown C; Oler RE; Fowler V; Wunderink RG
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33168615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies.
    Bai XR; Liu JM; Jiang DC; Yan SY
    J Chemother; 2018 May; 30(3):172-178. PubMed ID: 29405898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
    Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
    Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia.
    Xu L; Wang YL; Du S; Chen L; Long LH; Wu Y
    Chemotherapy; 2016; 61(6):323-30. PubMed ID: 27144279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia.
    Dimopoulos G; Almyroudi MP; Kapralos I; Apostolopoulou O; Flevari A; Nicolau DP; Dokoumetzidis A
    Int J Antimicrob Agents; 2022 Jan; 59(1):106487. PubMed ID: 34843925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
    Kuti JL; Dowzicky M; Nicolau DP
    J Chemother; 2008 Feb; 20(1):69-76. PubMed ID: 18343747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.
    Zheng Y; Liu SP; Xu BP; Shi ZR; Wang K; Yang JB; Huang X; Tang BH; Chen XK; Shi HY; Zhou Y; Wu YE; Qi H; Jacqz-Aigrain E; Shen AD; Zhao W
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B; Walker SAN
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
    Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of tigecycline in critically ill patients.
    Luo X; Wang S; Li D; Wen J; Sun N; Fan G
    Front Pharmacol; 2023; 14():1083464. PubMed ID: 36992827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.